Henry I. Miller, M.D., was a Research Fellow at the Hoover Institution and Adjunct Fellow at the Competitive Enterprise Institute. His research focuses on public policy toward science and technology, especially pharmaceutical development and the new biotechnology. His work often emphasizes the excessive costs of government regulation and models for regulatory reform.

Dr. Miller began his career as a research scientist at the National Institutes of Health in 1977, and he joined the Food and Drug Administration in 1979. While at the FDA, Miller served in several posts, including special assistant to the FDA Commissioner with responsibility for biotechnology issues, and he was the medical reviewer for the first genetically engineered drugs evaluated by the FDA. From 1989 to 1994, he was the founding director of the FDA’s Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the U.S. government, and he was the recipient of numerous awards and citations. After leaving the government, Miller became the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution, 1994–96.

His book, The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution (Praeger, 2004), co-authored with Gregory Conko, was named by Barron’s as one of the 25 best books of 2004. His other books include Policy Controversy in Biotechnology: An Insider’s View (R.G. Landes, 1997), Biotechnology Regulation: The Unacceptable Costs of Excessive Regulation (Social Affairs Unit, 1997), and To America’s Health: A Model for Reform of the Food and Drug Administration (Hoover Institution Press, 2000). His articles have appeared in many newspapers, including The New York Times, The Wall Street Journal, and the Financial Times of London. He is a regulator commentator on the nationally syndicated John Batchelor-Paul Alexander Program on ABC radio.

Dr. Miller has published extensively in prominent medical, scientific, and public affairs journals including The Lancet, Journal of the American Medical Association, Science, Nature, Nature Biotechnology. He is a member of the editorial boards of the Journal of Commercial Biotechnology, Human Gene Therapy, Medical Spectator, and Biotechnology Law Report. He is also an adjunct scholar at the Competitive Enterprise Institute, a member of the scientific advisory board of the George C. Marshall Institute and a director of the American Council on Science and Health.



More Op-Eds/Articles